On Monday, Celldex Therapeutics Inc (NASDAQ: CLDX) opened lower -6.25% from the last session, before settling in for the closing price of $27.38. Price fluctuations for CLDX have ranged from $14.40 to $30.50 over the past 52 weeks.
A company in the Healthcare sector has jumped its sales by 6.91% annually for the last half of the decade. Company’s average yearly earnings per share was noted -50.13% at the time writing. With a float of $64.55 million, this company’s outstanding shares have now reached $66.45 million.
Celldex Therapeutics Inc (CLDX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Celldex Therapeutics Inc is 2.86%, while institutional ownership is 107.39%. The most recent insider transaction that took place on Dec 04 ’25, was worth 121,210. In this transaction SVP & GENERAL COUNSEL of this company sold 4,166 shares at a rate of $29.09, taking the stock ownership to the 30,796 shares. Before that another transaction happened on Dec 04 ’25, when Company’s Officer proposed sale 4,166 for $29.10, making the entire transaction worth $121,210.
Celldex Therapeutics Inc (CLDX) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.71 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.71) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -50.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -24.98% during the next five years compared to 6.91% growth over the previous five years of trading.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Check out the current performance indicators for Celldex Therapeutics Inc (CLDX). In the past quarter, the stock posted a quick ratio of 13.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 656.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.38, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -4.50 in one year’s time.
